Male survivors of allogeneic hematopoietic stem cell transplantation have a long term persisting risk of cardiovascular events
| Autor: | Robert Q. Le, Sujata M Shanbhag, Sawa Ito, Priyanka A. Pophali, Christopher S. Hourigan, Bipin N. Savani, Kamna Chawla, Eleftheria Koklanaris, A. John Barrett, Natasha A. Jain, Minoo Battiwalla, Jeffrey K. Klotz |
|---|---|
| Rok vydání: | 2013 |
| Předmět: |
Adult
Male Cancer Research medicine.medical_specialty medicine.medical_treatment Population Hematopoietic stem cell transplantation Article immune system diseases Risk Factors Internal medicine hemic and lymphatic diseases Genetics medicine Humans Transplantation Homologous Survivors education Molecular Biology Acute leukemia education.field_of_study Framingham Risk Score business.industry Hematopoietic Stem Cell Transplantation Cell Biology Hematology medicine.disease Transplantation medicine.anatomical_structure surgical procedures operative Cardiovascular Diseases Immunology Female Bone marrow business therapeutics Body mass index human activities Dyslipidemia |
| Zdroj: | Experimental hematology. 42(2) |
| ISSN: | 1873-2399 |
| Popis: | Long-term survivors of allogeneic stem cell transplantation (SCT) have increased risk of cardiovascular disease. We retrospectively studied cardiovascular risk factors (CVRFs) in 109 SCT survivors (62 males, 47 females; median age 34 years) five years or more after bone marrow (15) or T cell-depleted peripheral blood (94) SCT for CML (56), acute leukemia (29), MDS (13), and others (11). One death and two cardiovascular events were reported. At five and ten years after SCT, respectively, 44% and 52% had abnormal lipid profiles; 23% of 5-year survivors met the Adult Treatment Panel III threshold for dyslipidemia treatment, which is substantially higher than the age-matched general population. There were significant increases in prevalence of hypertension (p0.001), diabetes (p = 0.018), and body mass index (p = 0.044) after SCT compared with baseline. The Framingham general cardiovascular risk score (FGCRS) in males at five years after SCT projected a doubling (median 10.4% vs. 5.4%) in the 10-year risk of cardiovascular events. Females received HRT after SCT, and none had increased FGCRS. Chronic GVHD and C-reactive protein were not associated with CVRF at any time. All CVRFs stabilized between five and ten years after SCT. Thus, SCT survivors have sustained elevations in CVRFs. Males have a significantly increased risk of cardiovascular events in their second and third decade after SCT. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect